BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...the €380 million takeout of NLRP3 company Inflazome Ltd....
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...the €380 million ($442.9 million) takeout of Dublin-based Inflazome Ltd....
...centerpiece of at least three acquisitions since 2018. Inflazome’s...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...with Roche’s €380 million takeout of Dublin-based Inflazome Ltd....
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...the co-founding investors in Inflazome Ltd., which Roche is acquiring for €380 million up front. Rogan was Inflazome’s...
BioCentury | Sep 24, 2020
Finance

Data Bytes: record fund for Longitude follows rush of deals, IPOs

...two largest European biotech acquisitions so far this year: the €380 million takeout of NLRP3 company Inflazome Ltd....
...Therapeutics Ltd. by Bayer AG (Xetra:BAY) for $425 million up front (see “Roche’s Deal for Inflazome”...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...with Roche’s €380 million takeout of Dublin-based Inflazome Ltd....
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...largest this year By stephen hansen, associate editor With its €380 million takeout of Dublin-based Inflazome...
...high profile venture-backed biotechs with NLRP3 inhibitors.According to Forbion’s Marco Boorsma, the decision to sell Inflazome Ltd....
...is the largest shareholder in Inflazome, co-leading the biotech’s €40 million series B round in 2018.  Altogether Inflazome...
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...is one of at least four companies with an NLRP3 inhibitor in Phase I testing. Inflazome Ltd....
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...potential for a safety issue and there’s a risk of not responding to infections,” said Inflazome Ltd....
...of their companies has disclosed programs in alternative targets. NodThera is “watching the space,” and Inflazome...
...However, NodThera and Jecure Therapeutics Inc. are both eyeing NASH for their lead indications, and Inflazome...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...AGT-110 AD, ALS, PD Preclin Inflammasome NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) Inflazome Ltd....
...of the inflammatory cytokines IL-1β and IL-18. In a Science Translational Medicine study last year, Inflazome Ltd....
...disease, an NLRP3 inhibitor decreased dopaminergic neuron degradation. Co-founder and CEO Matthew Cooper told BioCentury Inflazome...
Items per page:
1 - 10 of 24
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...the €380 million takeout of NLRP3 company Inflazome Ltd....
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...the €380 million ($442.9 million) takeout of Dublin-based Inflazome Ltd....
...centerpiece of at least three acquisitions since 2018. Inflazome’s...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...with Roche’s €380 million takeout of Dublin-based Inflazome Ltd....
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...the co-founding investors in Inflazome Ltd., which Roche is acquiring for €380 million up front. Rogan was Inflazome’s...
BioCentury | Sep 24, 2020
Finance

Data Bytes: record fund for Longitude follows rush of deals, IPOs

...two largest European biotech acquisitions so far this year: the €380 million takeout of NLRP3 company Inflazome Ltd....
...Therapeutics Ltd. by Bayer AG (Xetra:BAY) for $425 million up front (see “Roche’s Deal for Inflazome”...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...with Roche’s €380 million takeout of Dublin-based Inflazome Ltd....
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...largest this year By stephen hansen, associate editor With its €380 million takeout of Dublin-based Inflazome...
...high profile venture-backed biotechs with NLRP3 inhibitors.According to Forbion’s Marco Boorsma, the decision to sell Inflazome Ltd....
...is the largest shareholder in Inflazome, co-leading the biotech’s €40 million series B round in 2018.  Altogether Inflazome...
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...is one of at least four companies with an NLRP3 inhibitor in Phase I testing. Inflazome Ltd....
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...potential for a safety issue and there’s a risk of not responding to infections,” said Inflazome Ltd....
...of their companies has disclosed programs in alternative targets. NodThera is “watching the space,” and Inflazome...
...However, NodThera and Jecure Therapeutics Inc. are both eyeing NASH for their lead indications, and Inflazome...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...AGT-110 AD, ALS, PD Preclin Inflammasome NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) Inflazome Ltd....
...of the inflammatory cytokines IL-1β and IL-18. In a Science Translational Medicine study last year, Inflazome Ltd....
...disease, an NLRP3 inhibitor decreased dopaminergic neuron degradation. Co-founder and CEO Matthew Cooper told BioCentury Inflazome...
Items per page:
1 - 10 of 24